Remarks on Bootstrap Percolation in Metric Networks

We examine bootstrap percolation in d-dimensional, directed metric graphs in the context of recent measurements of firing dynamics in 2D neuronal cultures. There are two regimes, depending on the graph size N. Large metric graphs are ignited by the occurrence of critical nuclei, which initially occupy an infinitesimal fraction, f_* -> 0, of the graph and then explode throughout a finite fraction. Smaller metric graphs are effectively random in the sense that their ignition requires the initial ignition of a finite, unlocalized fraction of the graph, f_* >0. The crossover between the two regimes is at a size N_* which scales exponentially with the connectivity range \lambda like_* \sim \exp\lambda^d. The neuronal cultures are finite metric graphs of size N \simeq 10^5-10^6, which, for the parameters of the experiment, is effectively random since N<< N_*. This explains the seeming contradiction in the observed finite f_* in these cultures. Finally, we discuss the dynamics of the firing front

Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017 : a systematic analysis for the Global Burden of Disease Study 2017

Background: Previous attempts to characterise the burden of chronic respiratory diseases have focused only on specific disease conditions, such as chronic obstructive pulmonary disease (COPD) or asthma. In this study, we aimed to characterise the burden of chronic respiratory diseases globally, providing a comprehensive and up-to-date analysis on geographical and time trends from 1990 to 2017. Methods: Using data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017, we estimated the prevalence, morbidity, and mortality attributable to chronic respiratory diseases through an analysis of deaths, disability-adjusted life-years (DALYs), and years of life lost (YLL) by GBD super-region, from 1990 to 2017, stratified by age and sex. Specific diseases analysed included asthma, COPD, interstitial lung disease and pulmonary sarcoidosis, pneumoconiosis, and other chronic respiratory diseases. We also assessed the contribution of risk factors (smoking, second-hand smoke, ambient particulate matter and ozone pollution, household air pollution from solid fuels, and occupational risks) to chronic respiratory disease-attributable DALYs. Findings: In 2017, 544·9 million people (95% uncertainty interval [UI] 506·9–584·8) worldwide had a chronic respiratory disease, representing an increase of 39·8% compared with 1990. Chronic respiratory disease prevalence showed wide variability across GBD super-regions, with the highest prevalence among both males and females in high-income regions, and the lowest prevalence in sub-Saharan Africa and south Asia. The age-sex-specific prevalence of each chronic respiratory disease in 2017 was also highly variable geographically. Chronic respiratory diseases were the third leading cause of death in 2017 (7·0% [95% UI 6·8–7·2] of all deaths), behind cardiovascular diseases and neoplasms. Deaths due to chronic respiratory diseases numbered 3 914 196 (95% UI 3 790 578–4 044 819) in 2017, an increase of 18·0% since 1990, while total DALYs increased by 13·3%. However, when accounting for ageing and population growth, declines were observed in age-standardised prevalence (14·3% decrease), age-standardised death rates (42·6%), and age-standardised DALY rates (38·2%). In males and females, most chronic respiratory disease-attributable deaths and DALYs were due to COPD. In regional analyses, mortality rates from chronic respiratory diseases were greatest in south Asia and lowest in sub-Saharan Africa, also across both sexes. Notably, although absolute prevalence was lower in south Asia than in most other super-regions, YLLs due to chronic respiratory diseases across the subcontinent were the highest in the world. Death rates due to interstitial lung disease and pulmonary sarcoidosis were greater than those due to pneumoconiosis in all super-regions. Smoking was the leading risk factor for chronic respiratory disease-related disability across all regions for men. Among women, household air pollution from solid fuels was the predominant risk factor for chronic respiratory diseases in south Asia and sub-Saharan Africa, while ambient particulate matter represented the leading risk factor in southeast Asia, east Asia, and Oceania, and in the Middle East and north Africa super-region. Interpretation: Our study shows that chronic respiratory diseases remain a leading cause of death and disability worldwide, with growth in absolute numbers but sharp declines in several age-standardised estimators since 1990. Premature mortality from chronic respiratory diseases seems to be highest in regions with less-resourced health systems on a per-capita basis. Funding: Bill & Melinda Gates Foundation. © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. **Please note that there are multiple authors for this article therefore only the name of the first 5 including Federation University Australia affiliate “Muhammad Aziz Rahman” is provided in this record*

Outstanding aspects on the use of spent FCC catalyst in binders

4 pages, 3 fiures, 7 tables.-- En: 1st Spanish National Conference on Advances in Materials Recycling and Eco – Energy Madrid, 12-13 November 2009.-- Editors: F. A. López, F. Puertas, F. J. Alguacil and A. Guerrero.FCC is a waste material from petrochemical plants which has interesting properties for preparing binders. FCC is lightly grey in color, and white FCC-portland cements with L*≥85 can be prepared. FCC reactivity is enhanced by grinding and it is attributed to pozzolanic reaction towards lime. Stratlingite is the main hydrated product from pozzolanic reaction, and CSH and CAH are also formed. Reactivity of FCC is high, and low curing temperature does not affect this contribution to strength in hardened mixtures. Additionally, high strength concrete can be easily prepared, and compressive strength greater 100MPa can be reached. Mixtures with low w/b ratio showed good behaviour in carbonation tests.Authors thank to Ministerio de Ciencia y Tecnología of Spain and FEDER the financial support of MAT 2001-2694 and BIA 2004-0052 projects.Peer reviewe

Precise Modeling of the Exoplanet Host Star and CoRoT Main Target HD 52265

This paper presents a detailed and precise study of the characteristics of the Exoplanet Host Star and CoRoT main target HD 52265, as derived from asteroseismic studies. The results are compared with previous estimates, with a comprehensive summary and discussion. The basic method is similar to that previously used by the Toulouse group for solar-type stars. Models are computed with various initial chemical compositions and the computed p-mode frequencies are compared with the observed ones. All models include atomic diffusion and the importance of radiative accelerations is discussed. Several tests are used, including the usual frequency combinations and the fits of the \'echelle diagrams. The possible surface effects are introduced and discussed. Automatic codes are also used to find the best model for this star (SEEK, AMP) and their results are compared with that obtained with the detailed method. We find precise results for the mass, radius and age of this star, as well as its effective temperature and luminosity. We also give an estimate of the initial helium abundance. These results are important for the characterization of the star-planet system.Comment: 9 pages, 6 figures, 7 tables, to be published in Astronomy and Astrophysic

Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1

Introduction: The aim of this work is to assess the effect of upadacitinib versus adalimumab and placebo on patient-reported outcomes (PROs) in psoriatic arthritis (PsA) patients with inadequate responses to ≥ 1 non-biologic disease-modifying anti-rheumatic drugs (non-bDMARD-IR) in SELECT PsA-1. Methods: In this placebo- and active comparator, phase 3 randomized, controlled trial, patients received daily upadacitinib 15 or 30&nbsp;mg, placebo, or adalimumab 40&nbsp;mg every other week through 56&nbsp;weeks. At week 24, placebo-assigned patients were rerandomized to upadacitinib 15 or 30&nbsp;mg. PROs included Patient Global Assessment of Disease Activity (PtGA), pain, Health Assessment Questionnaire Disability Index (HAQ-DI), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Short Form 36 Health Survey (SF-36), EQ-5D-5L index score, Bath Ankylosing Spondylitis Disease Activity Index, morning stiffness, Self-Assessment of Psoriasis Symptoms, and Work Productivity and Activity Impairment. Mean changes from baseline in PROs, improvements ≥ minimum clinically important differences (MCID), scores ≥ normative values, and sustained clinically meaningful responses were compared between treatment groups. Results: At weeks 12 and 24, upadacitinib treatment resulted in improvements from baseline versus placebo across all PROs as well as improvements versus adalimumab in HAQ-DI and SF-36 Physical Component Summary score (nominal p &lt; 0.05). Improvements in PtGA, pain, and HAQ-DI were reported as early as week 2. At week 12, significantly (nominal p &lt; 0.05) more upadacitinib- versus placebo-treated patients reported improvements ≥ MCID across all PROs including seven SF-36 domains. The proportions of upadacitinib-treated patients reporting clinically meaningful improvements at week 12 were similar to or greater than with adalimumab and sustained through week 56. Significantly (nominal p &lt; 0.05) more upadacitinib-treated (both doses) patients reported scores ≥ normative values at week 12 versus placebo, and scores were generally similar to or greater than adalimumab. Conclusions: Upadacitinib treatment provides rapid, sustained, and clinically meaningful improvements in PROs in non-bDMARD-IR patients with PsA. SELECT-PsA 1 ClinicalTrials.gov number, NCT03104400

Acute kidney injury contributes to worse physical and quality of life outcomes in survivors of critical illness

Objectives: Survivors of critical illness and acute kidney injury (AKI) are at risk of increased morbidity. The purpose of this study was to compare physical, emotional, and cognitive health in survivors of critical illness with and without AKI. Methods: Retrospective cohort study of adult (≥ 18 years old) survivors of critical illness due to sepsis and/or acute respiratory failure who attended follow-up in a specialized ICU Recovery Clinic. Outcomes were evaluated during 3-month visit and comprised validated tests for evaluation of physical function, muscle strength, cognitive and emotional health, and self-reported health-related quality of life (HRQOL). Descriptive statistics and group comparisons were performed. Results: A total of 104 patients with median age of 55 [49-64] years, 54% male, and median SOFA score of 10 [8-12] were analyzed. Incidence of AKI during ICU admission was 61 and 19.2% of patients required renal replacement therapy (RRT). Patients with AKI stage 2 or 3 (vs. those with AKI stage 1 or no AKI) walked less on the 6-min walk test (223 ± 132 vs. 295 ± 153 m, p = 0.059) and achieved lower of the predicted walk distance (38% vs. 58%, p = 0.041). Similar patterns of worse physical function and more significant muscle weakness were observed in multiple tests, with overall worse metrics in patients that required RRT. Patients with AKI stage 2 or 3 also reported lower HRQOL scores when compared to their counterparts, including less ability to return to work or hobby, or reengage in driving. There were no significant differences in cognitive function or emotional health between groups. Conclusions: Survivors of critical illness and AKI stage 2 or 3 have increased physical debility and overall lower quality of life, with more impairment in return to work, hobby, and driving when compared to their counterparts without AKI or AKI stage 1 at 3 months post-discharge